Ironwood Pharmaceuticals Inc (FRA:I76)
€ 4.5 -0.04 (-0.88%) Market Cap: 713.95 Mil Enterprise Value: 1.21 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 56/100

Ironwood Pharmaceuticals Inc To Discuss The Topline Results Transcript

Feb 29, 2024 / 01:00PM GMT
Release Date Price: €11.8 (-15.11%)
Operator

Welcome to the Ironwood Pharmaceuticals conference call to discuss the positive top line results from global Phase 3 trial, a once weekly absolute group tied in adults with short bowel syndrome with intestinal failure.

I would now like to welcome Tom McCourt, Chief Executive Officer, to begin the call. Tom, over to you.

Tom McCourt
Ironwood Pharmaceuticals, Inc. - CEO & Director

Thanks, operator, and good morning, everyone. As the operator mentioned, I am Tom McCourt, Chief Executive Officer of Ironwood Pharmaceuticals, and I could not be more excited to join all of you to discuss the positive top line results from the pivotal Phase 3 STARS trial we announced earlier today. Before I begin, please take a moment to review our Safe Harbor statement as we will be making some forward-looking statements.

Today joining me today are Mike Shetzline, our Chief Medical Officer; Sravan Emany, our Chief Financial Officer; and Andrew Davis, our Chief Business Officer. Following our remarks, we'll open the call for a brief Q&A session.

We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot